- Home
- UFCS vs REPL Comparison
UFCS vs REPL Comparison
Compare UFCS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- REPL
- Stock Information
- Founded
- UFCS 1946
- REPL 2015
- Country
- UFCS United States
- REPL United States
- Employees
- UFCS N/A
- REPL 479
- Industry
- UFCS Property-Casualty Insurers
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- REPL Health Care
- Exchange
- UFCS Nasdaq
- REPL Nasdaq
- Market Cap
- UFCS 666.1M
- REPL 784.7M
- IPO Year
- UFCS N/A
- REPL 2018
- Fundamental
- Price
- UFCS $28.29
- REPL $9.83
- Analyst Decision
- UFCS Buy
- REPL Strong Buy
- Analyst Count
- UFCS 2
- REPL 6
- Target Price
- UFCS $30.00
- REPL $20.83
- AVG Volume (30 Days)
- UFCS 88.7K
- REPL 1.5M
- Earning Date
- UFCS 08-05-2025
- REPL 08-07-2025
- Dividend Yield
- UFCS 2.26%
- REPL N/A
- EPS Growth
- UFCS N/A
- REPL N/A
- EPS
- UFCS 2.54
- REPL N/A
- Revenue
- UFCS $1,288,423,000.00
- REPL N/A
- Revenue This Year
- UFCS $11.31
- REPL N/A
- Revenue Next Year
- UFCS $10.61
- REPL N/A
- P/E Ratio
- UFCS $11.16
- REPL N/A
- Revenue Growth
- UFCS 14.59
- REPL N/A
- 52 Week Low
- UFCS $18.04
- REPL $6.44
- 52 Week High
- UFCS $31.70
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- UFCS 51.46
- REPL 56.98
- Support Level
- UFCS $27.82
- REPL $9.50
- Resistance Level
- UFCS $28.82
- REPL $10.75
- Average True Range (ATR)
- UFCS 0.61
- REPL 0.67
- MACD
- UFCS -0.03
- REPL 0.05
- Stochastic Oscillator
- UFCS 54.70
- REPL 63.20
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.